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Abstract
Background and aims: Treatment goals in inflammatory bowel diseases are evolving beyond the
control of symptoms towards the tight control of objectively-measured gastrointestinal
inflammation. This review discusses the progress and challenges in adopting a treat-to-target
approach in inflammatory bowel diseases.
Methods: Evidence from the literature that highlights current thinking in terms of treating-
to-target in patients with inflammatory bowel diseases is discussed.
Results: Monitoring for objective evidence of inflammation using endoscopy, cross-sectional imaging
or laboratory biomarkers may be a useful approach in inflammatory bowel diseases; however, setting
the appropriate treatment goal remains a challenge. Deep remission (a composite of symptom control
and mucosal healing) may now be a realistic target in Crohn's disease; however, it remains to be
proven that achieving deep remission will modify the long-term disease course. Assessing prognosis at
an early stage of the disease course is essential for the development of an appropriate management
plan,with the rationale of adapting treatment to disease severity. An algorithmhas been proposed forimaging; CEUS, contrast-enhanced ultrasound; CRP, C-reactive protein.
tations made during the ‘Leading Change in IBD’ meeting held in Madrid on 18–19 January 2013 and
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928 W.J. Sandborn et al.the treatment of early Crohn's disease that involves early treatment with immunosuppressants and
tumour necrosis factor antagonists, in the hope of preventing structural bowel damage.
Conclusions: Treating beyond symptoms will require a clear management plan influenced by
disease severity at presentation, clinical and biological prognostic factors, achievement and
maintenance of clinical and biological remission and pharmacoeconomics.
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Early and optimised treatment tomeet specific targets is key to
preventing tissue damage and ultimately physical disability in a
number of chronic and progressive diseases including hyper-
tension, type 2 diabetes mellitus and rheumatoid arthritis.1–3
This treat-to-target approach has been facilitated by the
development of algorithms based on therapeutic targets
(which are modified to be more or less stringent in high-risk
patient groups); adoption of a frequent monitoring policy
where treatment is continually optimised until the target is
reached; and recognition of early disease states.2,4,5 In
inflammatory bowel diseases (IBD), current therapeutic goals
focus on induction and maintenance of clinical remission and
prevention of complications of both the disease and the
treatment. However, it is increasingly recognised that inflam-
matory activity persists even in the absence of gastrointestinal
symptoms, leading to progressive accumulation of bowel
damage including fistulae, abscesses and strictures in Crohn's
disease (CD),6,7 and fibrosis, dysmotility and colorectal neo-
plasm in ulcerative colitis (UC).8–10 Treatment goals in IBD are
therefore evolving beyond the control of symptoms alone
towards the sustained control of gastrointestinal inflammation,
measured objectively by endoscopic, radiologic and laboratory
parameters.
2. Setting appropriate treatment goals in IBD
The ideal treatment goal in any chronic disease is one that is
clearly defined, achievable with medical or surgical therapy,
predictive of long-term outcomes, affordable, non-invasive
and relevant across disease subtypes, with a low test-to-test
variability.In most current clinical practice, the primary goal of IBD
treatment is to induce and maintain clinical remission, with
therapeutic decision-making driven by the presence or
absence of clinical symptoms.11–13 However, achieving this
goal does not necessarily determine the clinical course of
the disease nor prevent long-term disease sequelae. Moni-
toring for objective evidence of inflammation using endos-
copy, cross-sectional imaging or laboratory biomarkers may
be a more useful approach; however, setting the appropri-
ate goal remains a challenge (Table 1).
Biomarkers, such as C-reactive protein (CRP) and faecal
calprotectin, may be useful for measuring disease activity
and guiding therapeutic decisions.14–17 However, test-to-test
variability, relevance across subtypes of IBD and ability to
predict long-term outcomes need to be more fully evaluated.
Achieving mucosal (endoscopic) healing is an important
prognostic feature of IBD treatment18,19 and prospective
studies are required to determine whether this outcome is a
feasible and necessary treatment goal. While a validated
definition of mucosal healing in IBD is still lacking, working
definitions are beginning to evolve. Laboratory markers may
also provide a surrogate measure of mucosal healing, although
more work is required to validate this approach.
With the advent of biologic therapies, it has become
apparent that deep remission (a composite of symptom
control and mucosal healing) may now be a realistic target in
CD.20–22 The definition of deep remission should include
considerations for both early and late disease,19 with early
disease including more stringent criteria. Patients diagnosed
late in the course of CD, those who already have pre-existing
disease complications or those who have required surgical
treatment may not be capable of achieving an absence of
clinical symptoms as a result of irreversible structural
damage inflicted by the CD itself or by surgical resection.
Table 1 Characteristics of potential treatment goals in inflammatory bowel diseases.
Endoscopy C-reactive
protein
Faecal
calprotectin
Magnetic resonance
imaging
GOAL No mucosal
lesions
Normalisation ? ?
Clearly defined goal ✓ ✓ ✗ ✗
Goal is achievable with medical or surgical therapy ✓ ✓ ✓ ✓
Achieving goal predicts long-term outcomes ✓ ? ? ?
Goal is relevant across IBD subtypes ✓ ✗ ? ✗
Measurement tool is affordable ✗ ✓ ✓ ✗
Measurement tool is non-invasive ✗ ✓ ✓ ✓
Tool has low test-to-test variability ✓ ✗ ✗ ?
929Treating beyond symptoms in IBDIn contrast, higher deep remission rates may be able to be
achieved in patients with early disease, as defined by time
from diagnosis and the absence of irreversible transmural
disease (strictures or fistula).19 While it remains to be
proven that treating to the point of deep or biologic
remission will affect the “natural course” of the disease, it
is intuitive that therapies providing greater levels of mucosal
healing and resolution of clinical symptoms may eventually
modify the disease course.23
3. Evidence for treating to target in IBD
While there is a plethora of evidence to support treating UC
and CD patients until they achieve clinical remission,24–32
there are limited data available for the efficacy of current
treatments in achieving other goals21,33–36 and what the
long-term outcomes of achieving such goals actually are
(summarized in Table 2). The potential risks of aiming for
tight disease controlmust also be considered, such as increased
toxicity, cost, increasingly complex treatment algorithms and
immunogenicity, as well as the modest risk and patient dis-
comfort associated with the increased use of endoscopic or
invasive procedures.
Another challenge of treating to target in IBD is that
acceptance of these treatment goals is not universal across
stakeholders; although many IBD specialists aim to treat
beyond the symptoms based on biomarkers and presence of
lesions, clinical remission is still an accepted goal for other
gastroenterologists, surgeons, non-specialist physicians,
patients and the authorities.
4. The importance of an accurate prognosis
Assessing prognosis at an early stage of the disease course in
IBD is essential for the development of an appropriate
management plan, with the rationale of adapting treatment
to disease severity. CD and UC are heterogeneous diseases
with some patients following a mild course and others
experiencing early and aggressive disease progression.37–39
Factors identified as potential predictors of an aggressive
disease course in CD include: age b 40 years at diagnosis,
presence of perianal lesions, the early need for steroids and
severe endoscopic lesions.40–43 In UC, potential negative
predictors include young age at diagnosis, extensive colitis,the presence of primary sclerosing cholangitis, non-smoker
status, need for early corticosteroids, intravenous corticoste-
roids and initial hospitalisation.43–45 A number of factors have
been identified that predict greater risk of requiring surgery;
these include non-colonic disease, penetrating disease,
smoking, male gender, early steroid use, severe endoscopic
lesions and some genetic loci in CD; and high stool frequency,
steroid use, severe endoscopic lesions, histological inflamma-
tion, high CRP and multiple single nucleotide polymorphism
scores in UC.41,43,46–52 In the future, it may be possible to
predict response to therapy using biomarkers16 or genetic
profiling53–56; however, more studies are needed to validate
these findings.
At present, there is a lack of specific and validated
serological and genetic markers for disease progression in IBD
and it is essential that prospective studies are conducted to
explore the use of combinations of predictive factors to help
us establish the prognosis for our patients. In the meantime, it
remains important to rely on our clinical experience, using our
knowledge of clinical characteristics, endoscopy, imaging
findings and laboratory biomarkers, to make rational clinical
decisions that aim to modify the disease course and delay
progression as far as possible.
5. Using imaging to tailor management of IBD
There are limitations in using clinical assessment of CD for
predicting the presence of active disease as it may have low
sensitivity and specificity to predict endoscopic lesions.57
Endoscopy is currently the gold standard for assessing
gastrointestinal inflammatory activity. The recent Post Oper-
ative Crohn's Endoscopic Recurrence (POCER) study evaluated
the utility of step-up therapy based on endoscopic targets
rather than clinical assessment in CD patients who had
undergone resection and were at high risk of recurrence.58
While this study showed that tailoring therapy based on
endoscopic findings is superior to current standards of care,
the impact of this strategy on clinical recurrence, disease
progression and disability has yet been to be fully ascertained.
Furthermore, one of the potential limitations of using endos-
copy to tailor treatment is that it is a relatively invasive
procedure. Therefore, it is important to assess if non-invasive
imaging techniques, such asmagnetic resonance imaging (MRI)
and ultrasound,may be of value to assess the disease course in
IBD.
930 W.J. Sandborn et al.5.1. Magnetic resonance imaging
The sensitivity and specificity of MRI for the detection of
active disease and correlation with segmental endoscopic
disease severity and detection of complications are high,
with more than 80% sensitivity and more than 90% specific-
ity.59 MRI has also been shown to be a valuable tool in the
assessment of response to therapy; pathological improve-
ments in MRI scans related to disease activity are responsive
and reliable indicators of endoscopic healing.60 Further-
more, in patients with ileal CD treated with infliximab,
severity of transmural and peri-enteric lesions as measured
by magnetic resonance enteroclysis has been shown to
correlate well with clinical response.61 Colonoscopy and
MRI have similar value in evaluating disease activity, but MRI
has greater success at identifying penetrating complica-
tions.62 This may lead to more timely initiation of more
potent therapeutic options or surgery.
5.2. Ultrasound
Ultrasound is useful for disease monitoring in CD.63 It is a
cost-effective and well-tolerated imaging technique in CD
that does not require the use of ionizing radiation. A meta-
analysis suggests that ultrasound may be a valid alternative
to CT and MRI for the evaluation of CD.64
In patients with inflammatory diseases in general, the
inflammation induces neoangiogenesis, which is a similar
phenomenon to that which occurs in neoplasia. This is a key
area of interest for ultrasound with colour Doppler imaging
(CDI) and contrast-enhanced ultrasound (CEUS), allowing for
subjective and quantitative evaluation of blood flow. CEUS
provides greater sensitivity for the detection of disease
activity compared with CDI alone.656. Algorithms for different patient types
All of the information gathered about a patient as they present
with IBD can be used to determine the most appropriate
management of that individual patient, including which
targets should be aimed for. However, it is still unclear as
to whether we should classify the patients according to
symptoms, course of disease, phenotype, complications, extra-
intestinal manifestations or a response or lack of response toTable 2 Evidence distribution for the different therapies across
Note that this is not an exhaustive summary of evidence evaluatin
Goal 5-ASA
Short-term endpoints
Clinical remission UC69
Steroid-free clinical remission ?
Clinical and endoscopic remission (deep remission) UC33,34
Treating beyond clinical and endoscopic remission ?
Long-term disease modification
Reduction of surgical risk ?
Reduction of disability ?
Reduction of ‘damage’ ?
5-ASA, 5-aminosalicylic acid; AZA, azathioprine.therapy. A combination of all these factors is used currently as
a basis for decisions. Several management approaches have
been developed for CD (Fig. 1). All require the balancing of
risks and benefits within the different treatment strategies.66
The conventional step-up care and accelerated step-up care
strategies are associated with lower efficacy, disease progres-
sion, a potentially higher risk of infections and mortality
associated with repeated corticosteroid use. They are not
likely to reduce the need for surgery and there is a high risk of
disease progression. The benefit of these approaches is lower
cost; moreover, many patients will achieve and maintain
remission in traditional step-up care and accelerated step-up
care approaches.
By comparison, early top-down therapy provides the
benefits of higher efficacy, a lower rate of disease-related
complications, higher rates of mucosal healing and, decreased
rates of surgery and hospitalisation. However, downsides
include a higher risk of drug-related serious infections and
higher costs. The elements needed to develop optimal
treatment strategies include patient profiling using prognostic
factors, establishing measurable treatment goals with an
acceptable benefit/risk profile and the early use of therapy to
achieve optimal patient outcomes, such as mucosal healing.
Several studies have shown significant treatment gains in
treating disease early.67,68
An algorithm has been proposed for the treatment of
early CD in patients with a disease duration of b2 years with
no previous use of immunomodulator therapy or TNF antag-
onists and the absence of pre-existing transmural complica-
tions (Fig. 2).66 The current challenge is to establish methods
for profiling patients and accepting that a patient's risk profile
is likely to change over time.
7. Summary and conclusions
Treating IBD beyond symptoms will require a clear manage-
ment plan influenced by disease severity at presentation,
clinical and biological prognostic factors, achievement and
maintenance of clinical and biological remission and pharma-
coeconomics. Prospective studies are required to confirm
prognostic factors, the relevance of individual disease targets,
the benefits and risk of treating-to-target on long-term
outcomes and the pharmacoeconomic value of a targeted
approach. Endoscopy, as well as cross-sectional imaging
techniques such as MRI and (in some instances) ultrasound,the short- and long-term goals in inflammatory bowel disease.
g the efficacy of therapy in achieving treatment goals.
Steroids AZA MTX Anti-TNF
UC, CD24 UC?, CD?25,70 CD26 UC, CD27
N/A CD28 CD26 UC + CD29–32
UC35 UC36 ? UC, CD21
? ? ? ?
? Conflicting71 ? UC, CD72
? ? ? ?
? ? ? ?
Figure 1 Conventional and evolving treatment strategies for Crohn's disease. In a conventional step-care regimen, corticosteroids
and immunosuppressants (IMS) are prescribed additively and sequentially as symptoms become more severe, with tumour-necrosis
factor (TNF) antagonists reserved for patients with refractory disease or intolerance to conventional therapies. In an accelerated
step-care regimen, IMS are introduced in patients with newly-diagnosed disease rather than waiting until patients become
steroid-dependent. As in the conventional regimen, TNF antagonists are reserved for patients with refractory disease or intolerance
to conventional therapies. In the early top-down regimen, patients with high risk of disease progression receive first-line combined
immunosuppression with IMS and a TNF antagonist in order to prevent irreversible bowel damage. The benefits of combined
treatment need to be balanced against the risk of serious infection and lymphoma, together with pharmacoeconomic considerations.
Figure adapted and reproduced from Ordás et al,66 with permission from BMJ Publishing Group. ©2011.
931Treating beyond symptoms in IBDshould be utilized to strengthen the accuracy of clinical
decision-making and disease management. Algorithms in IBD
require improved patient profiling, identifying and validating
predictors of the disease course, prognosis and drug response.
There needs to be agreement concerning the treatment
targets and systematic monitoring required to ensure that
targets are met. In the future, it may also be of benefit to
consider the creation of a risk score that will allow the
stratification of patients at diagnosis and various points along
their disease course.Conflict of interest
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